Press release
Odense, Denmark – April 8, 2026 – Inverna Therapeutics is pleased to announce its participation in the Oligonucleotides for CNS Summit Europe 2026, held April 21 – 23, 2026 in Amsterdam, Netherlands. Inverna will be represented by Chief Development Officer Pontus Klein, PhD, who has also been invited to join the panel discussion, “Differentiating Next-Gen Oligonucleotides for CNS Therapeutics: Safety, Stability & Competitive Advantage” (Wednesday, April 22, 8:30 AM).
Presentation details:
- Date: Wednesday, April 22, 2026
- Time: 8:30 AM
“We look forward to participating in this meeting, which closely aligns with Inverna’s strategy and approach focused on developing safer, more effective precision medicines, particularly for neurological disorders.”
said Pontus Klein, PhD.
About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
